| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.965454 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20260925080639 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 250826s2025 onca obs f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 041 | 0 |aeng|afre |
|---|
| 043 | |an-cn--- |
|---|
| 045 | |ay1y2 |
|---|
| 086 | 1 |aH82-67/2025-PDF |
|---|
| 100 | 1 |aZhang, Yvonne, |eauthor. |
|---|
| 245 | 10|aPressures behind the rising costs in Canadian private drug plans pre- and post- COVID-19 pandemic : |b2018-2023 = Pressions à l'origine de l'augmentation des coûts des régimes privés d'assurance-médicaments au Canada avant et après la pandémie de COVID-19 : 2018-2023 / |cYvonne Zhang. |
|---|
| 246 | 11|aPressions à l'origine de l'augmentation des coûts des régimes privés d'assurance-médicaments au Canada avant et après la pandémie de COVID-19 : |b2018-2023 |
|---|
| 264 | 1|a[Ottawa] : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c[2025] |
|---|
| 300 | |a1 online resource (1 page) : |bcolour illustrations |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |a"NPDUIS, National Prescription Drug Utilization Information System." |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"Private drug plans play an important role in the Canadian healthcare system, and costs are a major concern for plan sponsors. This study explores the key cost pressures for private drug plans, differentiating between short-term and long-term effects, and highlighting the impact of the COVID-19 pandemic"--Objective. |
|---|
| 546 | |aText in English and French. |
|---|
| 650 | 0|aDrugs|xPrices|zCanada|vStatistics. |
|---|
| 650 | 0|aPharmaceutical services insurance|zCanada|vStatistics. |
|---|
| 655 | 7|aStatistics|2lcgft |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body. |
|---|
| 788 | |tPressures behind the rising costs in Canadian private drug plans pre- and post- COVID-19 pandemic : |efre|w(CaOODSP)9.966241 |
|---|
| 856 | 40|qPDF|s524 KB|uhttps://publications.gc.ca/collections/collection_2026/cepmb-pmprb/H82-67-2025.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/rising-costs-poster2025.html |
|---|